Prometheus Biosciences Analysis
Prometheus Biosciences is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Prometheus Biosciences delisted stock analysis is to determine its intrinsic value, which is an estimate of what Prometheus Biosciences is worth, separate from its market price. There are two main types of Prometheus Biosciences' stock analysis: fundamental analysis and technical analysis.
The Prometheus Biosciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Prometheus Biosciences is usually not traded on Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day. Prometheus Stock trading window is adjusted to America/New York timezone.
Prometheus |
Prometheus Stock Analysis Notes
About 17.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 3.54. Prometheus Biosciences had not issued any dividends in recent years. The entity had 1:100 split on the 1st of November 2013. Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases . Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. Prometheus Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. To find out more about Prometheus Biosciences contact Mark McKenna at 858 684 1300 or learn more at https://www.prometheusbiosciences.com.Prometheus Biosciences Investment Alerts
| Prometheus Biosciences is not yet fully synchronised with the market data | |
| Prometheus Biosciences has some characteristics of a very speculative penny stock | |
| Prometheus Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 6.81 M. Net Loss for the year was (141.75 M) with loss before overhead, payroll, taxes, and interest of (106.04 M). | |
| Prometheus Biosciences currently holds about 95.96 M in cash with (123.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.35. | |
| Over 81.0% of the company shares are owned by institutional investors |
Prometheus Biosciences Upcoming and Recent Events
Earnings reports are used by Prometheus Biosciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 10th of August 2023 Upcoming Quarterly Report | View | |
| 8th of November 2023 Next Financial Report | View | |
| 30th of June 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 31st of March 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Prometheus Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 9.56 B.Prometheus Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Prometheus Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Prometheus Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Prometheus Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mark McKenna over a year ago Disposition of 178098 shares by Mark McKenna of Prometheus Biosciences subject to Rule 16b-3 | ||
Mark McKenna over a year ago Exercise or conversion by Mark McKenna of 122528 shares of Prometheus Biosciences subject to Rule 16b-3 | ||
Papa Joseph C over a year ago Acquisition by Papa Joseph C of 2278 shares of Prometheus Biosciences subject to Rule 16b-3 | ||
Marshall Keith W over a year ago Exercise or conversion by Marshall Keith W of 10000 shares of Prometheus Biosciences subject to Rule 16b-3 | ||
Mark McKenna over a year ago Exercise or conversion by Mark McKenna of 25000 shares of Prometheus Biosciences subject to Rule 16b-3 | ||
Marshall Keith W over a year ago Exercise or conversion by Marshall Keith W of 10000 shares of Prometheus Biosciences subject to Rule 16b-3 | ||
Mark McKenna over a year ago Exercise or conversion by Mark McKenna of 700 shares of Prometheus Biosciences subject to Rule 16b-3 |
Prometheus Biosciences Outstanding Bonds
Prometheus Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Prometheus Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Prometheus bonds can be classified according to their maturity, which is the date when Prometheus Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| US74348YAV39 Corp BondUS74348YAV39 | View | |
| US74348YDX67 Corp BondUS74348YDX67 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| PROSPECT CAP P Corp BondUS74348YEA55 | View | |
| US74348TAU60 Corp BondUS74348TAU60 | View | |
| US74348TAV44 Corp BondUS74348TAV44 | View | |
| PSEC 3437 15 OCT 28 Corp BondUS74348TAW27 | View |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Prometheus Biosciences to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Theme Ratings Now
Theme RatingsDetermine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Prometheus Stock
If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Global Correlations Find global opportunities by holding instruments from different markets |